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Abstract 
Aims: To understand the influences on recruitment to the Naltrexone Enhanced Addiction 
Treatment (NEAT) study, a randomised placebo-controlled trial of extended-release 
naltrexone (XR-NTX) implants for opioid use disorder (OUD), to learn lessons for the design 
and conduct of similar future research.  
Methods: 29 face-to-face, semi-structured qualitative interviews were conducted with 
patients recruited to NEAT (n=6), patients not recruited (n=11), researchers who designed 
the trial (n=5), and staff who delivered the trial (n=7). The social marketing mix was used as 
a framework to guide the data analyses. 
Results: Dimensions of the 7Ps of the social marketing mix - product, price, place, 
promotion, physical environment, people, and processes all influenced recruitment to the 
NEAT trial. Amongst other things, the potential to receive a naltrexone implant (product); the 
provision of transport passes and shopping vouchers (price); clear verbal explanations 
(promotion); familiarity of the trial setting (physical environment); and approachable, friendly 
and informative trial delivery staff (people) positively influenced recruitment. Whereas, 
wanting a less medical approach to recovery (product); the perceived time, physical, and 
psychological costs of taking part (price); service ideological opposition to naltrexone in 
recovery (place); inaccessible written information (promotion); the location and nature of the 
trial setting (physical environment); a lack of knowledge about implants (people); and the 
blind allocation and potential of placebo (processes) deterred people from joining the trial. 
Conclusions: Qualitative research informed by the social marketing mix as an analytical 
framework yielded detailed insights into understanding the factors and circumstances that 
influenced recruitment to the NEAT trial. Our findings have implications for the planning and 
implementation of future addiction trials, especially trials of extended-release formulations.  
Keywords: Clinical trial; naltrexone; opioid dependence; qualitative; social marketing; study 
recruitment 
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Abbreviations 
Extended-release naltrexone (XR-NTX) 
Naltrexone (NTX) 
Naltrexone Enhanced Addiction Treatment (NEAT) 
Opioid use disorder (OUD) 
Oral naltrexone NTX (O-NTX) 
 
 
Highlights 
• Naltrexone (NTX) is an approved treatment for opioid use disorder (OUD) 
• The evidence base for extended-release implantable naltrexone (XR-NTX) for OUD 
is in its infancy 
• A clinical trial of oral and implant NTX in contrast to placebo struggled to recruit 
patients 
• Qualitative interviews with patients and trial staff explored what influenced 
recruitment 
• Social marketing offers an analytical framework to explore recruitment to clinical trials 
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1. Introduction 
Naltrexone (NTX) is an approved treatment for opioid use disorder (OUD) (Gowing et al., 
2014; NICE, 2007; SAMHSA, 2018), a chronic, relapsing condition affecting millions of 
people worldwide (United Nations, 2018). Unlike full or partial opioid agonist medications 
such as methadone and buprenorphine, naltrexone is an antagonist which binds to the 
brain’s receptors to block the effects of opioids. Consequently, NTX can be prescribed as a 
pharmacological relapse prevention strategy following opioid withdrawal.  
 
Studies of the effectiveness of oral (tablet) NTX (O-NTX) for the treatment of OUD have 
been compromised by poor adherence to daily dosing and low retention rates in treatment 
(Adi et al., 2007; Minozzi et al., 2011). Issues with adherence to oral naltrexone prompted 
the development of long-acting extended-release injectable and implantable formulations 
(XR-NTX) (Friedmann et al., 2018; Goonoo et al., 2014; Jarvis et al., 2018). Designed to 
reduce the frequency of dosing by modifying the rate of release and absorption, these newer 
formulations are similar to each other in that they typically deliver therapeutic levels of 
naltrexone that last at least one, and up to seven, months (Jarvis et al., 2018). However, 
injectable and implantable NTX differ in that injectable NTX does not involve a surgical 
incision and insertion procedure and it cannot be removed after administration.  
 
Injectable XR-NTX is now approved for the treatment of OUD in the United States (US) and 
Russia (Jarvis et al., 2018; SAMHSA, 2018). Implantable XR-NTX is only officially approved 
for use in Russia, but it is sometimes prescribed ‘off label’ under special circumstances, 
including in Australia and in a few private clinics in the United Kingdom (Krupitsky, Zvartau & 
Woody, 2010; Larney et al., 2014). Oral naltrexone is the only form of NTX licensed for use 
in the treatment of OUD in the UK and across Europe.  
 
The evidence base for XR-NTX for OUD is developing (Friedmann et al., 2018). A 
Norwegian noninferiority trial concluded that injectable XR-NTX was as effective as daily oral 
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buprenorphine-naloxone in retaining patients in treatment, reducing the number of days 
injecting and craving for opioids, and reducing illicit drug use (Tanum et al., 2017). 
Additionally, a randomised controlled trial (RCT) in the US found it as safe and effective (Lee 
et al., 2018); although difficulties initiating inpatients to injectable XR-NTX in the study 
impacted on its ability to prevent opioid use or promote abstinence (Lee et al., 2018). This 
latter finding is supported by a systematic review which concluded that issues with initiation 
and premature discontinuation significantly limit the clinical utility of injectable XR-NTX 
(Jarvis et al., 2018). Further trials indicate that XR-NTX implants effectively reduce relapse 
to heroin use when compared with O-NTX (Hulse et al., 2009; Krupitsky et al., 2012) or 
placebo medication (Krupitsky et al., 2012; Tiihonen et al., 2012) or usual aftercare (Kunøe 
et al., 2009) and improve retention in treatment (Krupitsky et al., 2012; Tiihonen et al., 2012). 
However, another systematic review cautioned that the quality and quantity of evidence on 
the safety and efficacy of XR-NTX implants is limited and called for better evidence (Larney 
et al., 2014).  
 
In recent years, researchers have begun to document their experiences of recruiting people 
with OUD to clinical trials, including the challenges faced (Demaret et al., 2014; Gartry et al., 
2009; Melberg & Humphreys, 2010; Oviedo-Joekes et al., 2009; Oviedo-Joekes et al., 2015; 
Thomson et al., 2008). For example, the prospect of desirable treatments that are otherwise 
unavailable and the provision of incentives have encouraged recruitment to trials (Oviedo-
Joekes et al., 2015; Thomson et al., 2008). Meanwhile, concerns about being allocated to 
placebo medication and other control conditions, personal medication preferences, and 
perceived excessive demands on participants have deterred participation (Demaret et al., 
2014; Melberg & Humphreys, 2010; Thomson et al., 2008). Nevertheless, there is little 
empirical research into what influences participation in pharmacological addiction trials 
(Demaret et al., 2014; Neale et al., 2018a) and we lack detailed insights into why people 
agree or refuse to take part (Kunøe et al., 2009; Melberg & Humphreys, 2010; Oviedo-
Joekes et al., 2015; Tiihonen et al., 2012). 
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Information on the recruitment of participants to XR-NTX implant trials is particularly scarce. 
Among the few NTX implant trials conducted to date, the desire to have active medication 
appears to have deterred participation in a trial of active and placebo implants (Hulse et al., 
2009). Likewise, roughly 60% of 111 prisoners screened to take part in an open-label trial 
comparing XR-NTX implants and methadone treatment after release declined to participate, 
often as they wanted to maintain abstinence by relying on their own resources (Lobmaier et 
al., 2010b). Furthermore, 7 of the 23 prisoners randomised to XR-NTX implants did not 
initiate treatment as they wanted opioid maintenance treatment (Lobmaier et al., 2010a). 
Other trials involving active or placebo XR-NTX implants have also met refusals to take part 
both before and after randomisation (Kunøe et al., 2009; Tiihonen et al., 2012).  
 
In 2010, the National Institute for Health Research (NIHR), Health Technology Assessment 
(HTA) Programme called for a three-arm randomised controlled double-dummy trial into 
sustained release naltrexone for opioid dependence (HTA, 2010) after their commissioned 
systematic review of oral naltrexone was inconclusive (Adi et al., 2007). Reflecting the 
requirements of the NIHR HTA call (HTA, 2010), the Naltrexone Enhanced Addiction 
Treatment (NEAT) trial was designed to explore the effectiveness of active XR-NTX implants 
and O-NTX in contrast to placebo medication in people with OUD seeking treatment to help 
them stay abstinent. Although the NIHR call for research did not request a pilot study, break-
points were included in the full trial design to ensure that clinical and operational problems 
were assessed and rectified whenever possible in the early stages and the trial would be 
terminated if any difficulties could not be adequately addressed. Detailed information on the 
randomisation, clinical interventions, dosing regimens, and visit schedule is available 
elsewhere (Strang et al., in press). Key features of the trial are outlined in Box 1.  
 
Box 1 here 
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The trial aimed to recruit 300 participants (100 to each intervention group). However, in spite 
of approaching 83 patients, only six patients were recruited in eleven months. The trial 
closed prematurely with the determination that recruitment to the study was not feasible in 
the current context.  
 
We subsequently conducted a qualitative study to better understand the factors affecting 
recruitment and to learn lessons for the design and conduct of similar future research. This 
paper reports our findings, focusing on what influenced recruitment to the trial from the 
perspective of patients and staff. We draw on social marketing to frame our analyses, an 
approach which has previously been used to explore and promote recruitment in clinical 
trials (Dunleavy et al., 2018; Kobayashi et al., 2013; Nichols et al., 2004).  
 
 
2. Methods 
Ethical approval for the qualitative study was obtained from the London Dulwich Research 
Ethics Committee in July 2017 (Ref: 14/LO/1615). 
 
2.1 Sampling and recruitment 
Staff who delivered the trial provided the qualitative researcher (CT) with the details of the 
six people recruited to NEAT (referred to from herein as NEAT patients) and an anonymised 
list of 83 patients who had been approached about taking part in the trial, but who did not 
join the trial. CT identified 30 people not recruited to NEAT (referred to from herein as non-
NEAT patients) from the list with different reasons for non-participation. Due to consent and 
data protection issues, trial delivery staff could only approach individuals who remained in 
methadone or buprenorphine treatment (n=14) to seek permission to pass their name and 
contact details to the researcher. Of the 14 patients still in treatment, three individuals could 
not be contacted. CT then contacted the six NEAT patients and 11 non-NEAT patients, 
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explained the study, and arranged interviews. CT also organised staff interviews with the 
researchers who designed the NEAT trial and the trial delivery staff. 
 
2.2 Data collection 
In late 2017, CT conducted 29 face-to-face interviews with NEAT patients (n=6), non-NEAT 
patients (n=11), researchers who designed the NEAT trial (n=5), and NEAT trial delivery 
staff (n=7) (Tables 1 and 2). All participants provided written consent. Interviews took place 
in private and were audio recorded. 
 
Tables 1 and 2 here 
 
Separate topic guides were developed for patients and staff. Nonetheless, all were 
encouraged to discuss their views and experiences of the trial, including the screening and 
sign-up processes, information received about the trial, and what encouraged or 
discouraged them to take part in the trial. In addition, patients were questioned about their 
drug use and treatment histories; staff were asked how organisational factors affected 
recruitment. 
 
Interviews with NEAT patients lasted between 63 and 92 minutes; non-NEAT patient 
interviews were shorter, between 36 and 65 minutes. The NEAT trial research staff and 
delivery staff interviews lasted between 52 and 104 minutes. 
 
2.3 Analytical framework 
Social marketing is an approach aimed at changing or maintaining behaviour for the benefit 
of individuals and society (National Social Marketing Centre (NSMC), 2011). In social 
marketing, the marketing mix is used to gain a detailed understanding of the target market’s 
attitudes, which can be altered to promote an intervention or service to achieve behavioural 
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change. The social marketing mix extends the commonly accepted ‘4Ps’ of traditional 
marketing - product, price, place, and promotion to include other relevant components, as 
outlined in Box 2.  
 
Box 2 here 
 
2.4 Data management and analyses 
All interviews were professionally transcribed verbatim. The transcripts were managed 
following the stages of Iterative Categorization (Neale, 2016). Firstly, CT developed separate 
patient and staff coding frames based on the topic guides and the interview discussions in 
the qualitative data software package, MAXQDA. The coding frames included separate 
codes for ‘encouraged participation’ and ‘discouraged participation’, each encompassing 
several sub-codes. Within each MAXQDA framework, CT then systematically coded the 
transcripts line-by-line by attributing portions of text to the relevant code/s. 
 
After coding all transcripts, the ‘encouraged participation’ and ‘discouraged participation’ 
codes were exported from the patient and staff MAXQDA frameworks into separate 
Microsoft Word documents for inductive analyses. That is, CT read each patient Word 
document and methodically grouped and organised the data, keeping like with like. She 
repeated the exercise with the staff data. During the final stage of the analyses, CT mapped 
the groups of coded data to the 7 areas of the social marketing mix. Finally, the mapped 
data were compared for similarities and differences in the views and experiences of NEAT 
patients, non-NEAT patients, researchers, and delivery staff. 
 
 
3. Findings 
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Below we report the NEAT trial recruitment experiences, with verbatim quotations from 
interview participants to highlight key points. 
 
3.1 Product 
Patients discussed how features of the trial influenced decisions to take part in it. Individuals 
who wanted to cease illicit opiate use tended to be most interested in taking part as they 
believed that the trial offered a ‘chance’ to become opiate-free and move on with their lives. 
 
I don’t want to take drugs, I want to live my life, I want to get back to work and be the 
person I once was. And at that stage I would have tried any trial or whatever going to 
help me do that. And it was just perfect timing really that I found out about the NEAT 
trial, and I put myself forward for it. (P17, female) 
 
Patients explained that the trial offered the potential for abstinence due to the antagonist 
properties of naltrexone to ‘block’ the effects of opioids. In particular, patients reported that 
the prospect of receiving an XR-NTX implant encouraged them to take part as they believed 
it would safeguard against opiate use. Thus, patients said that the trial provided a unique 
‘opportunity,’ commenting that naltrexone implants were otherwise only available from a 
private clinic, at a high price. 
 
I wanted to get an implant because I thought that would be fantastic… it would 
guarantee me a three-month period of absolute total abstinence. (NP11, male) 
 
A second feature of the trial which encouraged a few patients to take part was the provision 
of weekly counselling with a keyworker. However, this also hindered recruitment as other 
patients worried that the counselling may be ‘probing’ and overly intrusive. Staff expressed 
disappointment that the offer of weekly counselling did not attract more recruits. 
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Concerns about the trial medication also discouraged patients from joining NEAT. Patients 
reported that they were largely unfamiliar with oral and implant NTX and they deliberated 
about taking part in the trial after they learned of possible side effects. They also commonly 
shared anxieties about the form of the trial medication. For example, patients expressed 
anxiety about the implant insertion, were concerned about the semi-permanence and 
possible complications of an implant, and worried that the trial implant was insufficiently 
tested.  
 
It worry me because I think about implant. I’m not saying it’s wrong, I’m not saying it’s 
bad, but we don’t have no experience, nobody had done it, and they hope it’s a good 
medication, and they hope that it will work... I didn’t accept myself. (NP7, male) 
 
Other patients reported that they had not joined the trial because they wanted a less medical 
approach to recovery after spending many years on pharmacological treatment for OUD.  
 
I knew I didn’t want to do it [enrol in the trial] straight away… I didn’t want any more 
medication or anything else in my body. (NP8, male) 
 
In this way, trial delivery staff suggested the trial was at odds with how drug treatment 
services encouraged patients to develop resilience and self-efficacy in preparation for 
recovery. 
 
3.1.1 Competition 
Staff believed that the limited prescription of NTX within the range of treatment services 
recruiting patients encouraged interest in the NEAT trial. Nevertheless, uptake to the trial 
faced competition from the 12-step model of addiction treatment. Patients who followed this 
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approach said that they favoured spirituality and mutual aid to support abstinence and 
recovery over pharmacological treatment.  
 
I’ve been in recovery for several years, and the fellowship and things like that have 
helped… they use more of a spiritual approach... that stuff is more useful to me than 
a tablet... The whole point of me being here is to get back my life, not a tablet to aid 
me in doing that, there’s not a pill for such a thing. (NP5, male) 
 
The desire to use opioids also influenced recruitment to the trial. That is, some patients 
reported that the potential allocation to active NTX deterred them from enrolling in the trial as 
they did not want the effects of opiates to be ‘blocked’.  
 
I thought, I don’t know if I really want to take this thing just to block out everything… if 
something happens I might want to have a fix [use drugs]… I just knew I wasn’t going 
to do it [enrol in the trial]. (NP9, male) 
 
Others explained that they were deterred from taking part as they worried that NTX might 
change how they experienced the effects of alcohol. Similarly, patient satisfaction with 
current methadone or buprenorphine maintenance or fear of losing the ‘security’ of this 
treatment competed with the trial and hindered uptake, as did pre-existing treatment plans to 
be drug and medication-free.  
 
3.2 Price 
Uptake to the NEAT trial was influenced by the perceived costs of taking part. Some patients 
believed that attending the clinic three times a week for 12 weeks for the trial would keep 
them occupied after detoxification, encouraging them to take part. More often however, 
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patients insisted that the number of visits would be ‘inconvenient’ and ‘a hassle’ when 
rebuilding their lives following abstinence.  
 
We had to go in there three times a week… I can handle once a week maybe, but 
three times a week is quite a big thing. (NP6, female) 
 
The time involved in attending clinic visits concerned patients with work or family 
commitments. Trial delivery staff also noted that screening was time consuming and involved 
‘intensive’ assessments and ‘form-filling’. Furthermore, patients worried about what might 
happen to their future contact with the service and their entitlement to receive social welfare 
benefits related to ill-health if they became abstinent and took part in the trial. 
 
Patients also considered physical costs of taking part. Pain, scarring and possible site 
reactions or complications of being ‘sliced’ or ‘cut open’ to receive an implant commonly 
discouraged people from joining the trial, especially if they said that they were ‘squeamish’ or 
if they reported negative experiences of medical procedures in the past. 
 
The implant involved having to cut someone… cut open their skin and put it in under 
their skin. And the patient didn’t want this, put loads of patients off. (S7, researcher) 
 
Coupled with this, other costs which influenced patient uptake to the trial were more 
psychological in nature and stemmed from the blind allocation of treatment, the potential 
allocation to double placebo (including a dislike of the requirement to undergo a surgical 
procedure to receive a placebo implant), and the possibility of feeling ‘trapped’ and with 
reduced choice over opioid use if allocated an active implant. 
 
**Article accepted for publication in Journal of Substance Abuse Treatment, Jan 2019** 
16 
Nevertheless, those recruited to the trial considered that the benefits of taking part 
outweighed the perceived costs. For instance, even when considering the potential of 
allocation to double placebo, patients viewed the chance of allocation to active oral or 
implant naltrexone as favourable. 
 
You’re two thirds likely to have something active, and one third likely to have… 
nothing active. So, either you’ve got one third possibility of having an active implant, 
one third possibility of having active pills, and one third possibility of having an 
inactive implant and inactive pills… I liked the odds… I wanted something to be real, 
because I knew that the drug did have an effect on heroin. (P13, male) 
 
Additionally, NEAT patients said that the provision of public transport passes and shopping 
vouchers to attend trial appointments minimised perceived financial costs and encouraged 
them to join the trial; some claimed that they would not have taken part without 
reimbursement.  
 
I was going to get paid for doing it… you get £25 a week vouchers... I don’t think I 
would have done it for free. (P15, female) 
 
3.3 Place 
Staff explained that the recent recommissioning of community addictions services locally had 
resulted in the loss of one of the three delivery settings before the trial had started and had 
caused significant changes in service provision in another of the locations. Staff outlined how 
their subsequent attempts to extend the trial to include further recruitment sites were 
unsuccessful, again related to local and sector-wide changes in the tendering, 
commissioning, and provision of services. Staff lamented how these issues undermined 
recruitment. 
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There’s carnage in the addictions field at the moment… contracts that are churning 
and changing so two of the centres never got off the ground… your hands are tied… 
you’re already two thirds down... that’s a more global reason, why we struggled to 
recruit. (S7, researcher) 
 
Although the NEAT trial was offered in various inpatient and outpatient services, staff 
reported that availability of the trial was influenced by a change of environment in the 
addictions field at the time of NEAT. Specifically, staff reported that the unexpected closure 
of inpatient detoxification units prevented the referral of potential patients to the trial and 
affected study recruitment. Furthermore, some referral services did not support the use of 
NTX in recovery on ideological grounds and this compounded recruitment problems. 
 
They [residential rehabilitation service] were quite clear that their whole philosophy is 
about teaching clients to manage emotions without drugs, and that you don’t need 
drugs, and therefore naltrexone goes against that. (S4, delivery staff) 
 
Additionally, staff noted that referral to, and uptake of, the trial was hindered when service 
workers who could refer eligible patients to the trial were stretched with heavy workloads. 
Trial delivery staff reported that they could not always attend each service to encourage 
referrals, which limited recruitment. 
 
3.4 Promotion 
Patients reported that their first impressions of NEAT were of a professional and well-
presented study. Underpinning these perceptions, patients observed that the trial was being 
conducted within reputable NHS treatment services by respected academics and clinicians. 
They commented that their confidence in, and understanding of, the trial was aided when 
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trial delivery staff provided them with clear verbal explanations and answered their 
questions.  
 
It was well versed, well presented, it was well spoken about. I mean it was 
confidently put across to me. No way did I feel like this person don’t know what 
they’re on about. (NP5, male) 
 
Delivery staff confirmed that the use of simple language and sketches when they explained 
the trial to potential patients aided comprehension and ultimately uptake. They noted that 
face-to-face communication was more successful in recruiting participants than promoting 
the trial by adverts. Yet trial delivery staff cautioned that promotion was compromised if other 
demands were made on their time. 
 
The drug service itself was going through a period of change, staff shortages, staff 
cuts… for the trial I don’t think it was the best thing… I was getting pulled in a few 
different directions. (S9, delivery staff) 
 
In contrast, patients and delivery staff commonly complained that the trial information leaflet 
was too long, ‘wordy,’ and inaccessible, especially for patients with limited education or from 
low socio-economic groups. Patients with reading difficulties or whose first language was not 
English reported problems understanding the written information. 
 
I didn’t actually read it, but it was about 4 or 5 bits of paper… I’m dyslexic. I sort of 
start reading something and I get bored. (P1, male) 
 
3.5 Physical environment 
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Staff believed the community addiction services were suitable locations for delivering the trial 
as they had the facilities to store trial medications, conduct the implant surgery, and monitor 
participants. 
 
A few NEAT patients reported that the reputation and familiarity of the delivery service 
encouraged them to participate in the trial. More often, patients said that they did not want to 
attend a ‘frontline’ drug service when trying to distance themselves from drugs. They 
reported that they were wary about taking part in the trial as the service was located in a 
prolific drug-using area and they found the service environment ‘chaotic’. Most commonly, 
they feared that seeing drug users when attending trial appointments may trigger cravings to 
use heroin.  
 
Going to [drug service] is a nightmare… I start getting panicky, and I think who am I 
going to bump into in that waiting room? You know, most people in there are still 
heavily using, so if I’m clean, it’s not somewhere I really want to go. (NP6, female) 
 
Proximity to the service also influenced recruitment – having further to travel and 
complications with transport put some patients off. Furthermore, patients from neighbouring 
services raised concerns about travelling to and attending an unfamiliar service when they 
anticipated feeling ‘physically uncomfortable’ and ‘emotionally vulnerable’ after detoxification. 
 
3.6 People 
Staff and patients highlighted that the qualities, availability, and knowledge of the NEAT trial 
delivery staff promoted recruitment to the trial. The trial researchers praised the dedication of 
the trial delivery staff. All staff believed that prior experience of working with people who use 
drugs enabled the delivery staff to form relationships when introducing the trial to potential 
participants. 
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They hired amazing staff members to do it, who are so friendly and approachable, 
and that’s really, really key. (S8, delivery staff) 
 
Similarly, patients reported that the those delivering the trial were approachable, friendly, 
informative, and supportive which helped them to ask questions about the trial and 
contemplate taking part. However, a patient who wanted to join the trial reported being 
dissuaded when a member of trial staff could not answer their question about NTX implants. 
Trial delivery staff confirmed that insufficient knowledge about implants sometimes 
influenced recruitment. 
 
We’d never worked with these implants… we didn’t quite know what to expect. So it 
was very difficult, we couldn’t reassure people, because we didn’t know… when 
people ask you questions in a research trial, you want to have an answer… when 
you don’t have that answer, that somehow changes the whole dynamics. (S2, 
delivery staff) 
 
Staff believed that the co-location of delivery staff within community addiction service 
encouraged relationships with the service staff, promoted referrals, and helped recruitment. 
For example, patients felt encouraged to trust the trial staff and consider the trial if a service 
keyworker with whom they had established relationships introduced the trial.  
 
Luckily, we were based in the same office as the opiate teams, we could just have 
conversations, sometimes someone would call me over to discuss a potential 
participant… Being based where we were was the best decision, I think in terms of 
having a presence and access to patients. (S9, delivery staff) 
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Yet, patients sometimes struggled to inform trial delivery staff of decisions not to take part, 
for fear of disappointing them or their keyworkers. Occasionally, staff also suggested that 
recruitment was hampered when service keyworkers did not refer patients out of concern 
that the trial may threaten patient progress or stability in treatment. 
 
3.7 Processes 
NEAT trial patients welcomed having time to make an informed decision about taking part 
and to detoxify at their own pace. In addition, staff and patients felt that taking O-NTX in the 
pre-trial period helped patients to remain abstinent prior to joining the trial. 
 
Trial patients understood there was a chance of getting double placebo but saw this as ‘luck 
of the draw’ and accepted this as a common feature of trial design. On the other hand, 
patients said that the blind allocation of treatment and the potential allocation to placebo at a 
time of potential withdrawal and physical discomfort made them hesitant about taking part.  
 
I can understand why it [the trial] failed… if you said to me as someone coming off 
drugs, that you could be on this trial, and you’re not going to know whether this drug 
is actually going to help you or not, or whether you’re in a group that’s even going to 
get it… how can you almost live your life, not knowing what, how you’re going to feel 
tomorrow or the next day? (NP4, male) 
 
Compounding this, staff and patients frequently reported that the requirement to be 
completely abstinent from opioids for several days prior to joining the trial was a major 
barrier to recruitment. Concerns about feeling physically uncomfortable following 
detoxification also deterred some patients from taking part in the trial. 
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It had to happen within a week after coming off the medication. I was quite wary that 
that was going to be a big difficulty... you are asking people to do something… that 
has an inbuilt kind of, unknown quantities in it at a period where they least want that 
kind of feeling. (NP10, male) 
 
Others who wanted to take part said that remaining abstinent was demanding and joining the 
trial was risked if they relapsed or if trial appointments were re-scheduled. 
 
Trial delivery staff and patients also explained that intense screening processes deterred 
uptake to the trial, as patients often had to attend more than once to complete the required 
medical tests and assessment measures. Indeed, a patient who had detoxified for the trial 
changed his mind about taking part following ‘extensive questionnaires’ and ‘intensive’ 
screening. 
 
Although trial delivery staff praised the flexibility and availability of the implant consultant, 
patients who completed screening occasionally reported that waiting for an implant 
appointment nearly prevented them from joining the trial. Likewise, those who designed the 
trial worried that the time between screening and consent to take part risked losing recruits. 
 
We then put you through a process of saying, ‘we’ll arrange an appointment for us to 
go over… the trial procedures, at the end of which you can give consent, at the end 
of which we then allow you a cooling off period, and if you then say yes, we’ll then 
book you in for the surgical minor ops procedure of having the implant’… Suddenly a 
week has gone… the critical week that you want to capture. (S6, researcher)  
 
 
4. Discussion 
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This qualitative study explored what influenced recruitment to a randomised controlled trial of 
the effectiveness of XR-NTX implants and O-NTX for OUD. We conducted the study to learn 
lessons after the NEAT trial closed prematurely after failing to recruit participants as 
planned. 
 
As we only interviewed patients who remained in treatment for OUD, the findings may not 
transfer to people who had left treatment after being approached about the trial. 
Furthermore, as interviews took place between 8 and 24 months after patients had been 
approached or involved in the trial, the accounts may be subject to recall bias.  
 
Unlike existing reports of the experiences of recruiting people with OUD to clinical trials 
which tend to focus on the anecdotal perspectives of either staff or patients, a strength of our 
study is that we obtained and analysed first-hand accounts from staff and patients involved 
in the NEAT trial. That is, we interviewed all patients who were recruited to the trial and all 
staff involved in its design and delivery, including members of staff who had moved on after 
the trial. Obtaining these multiple perspectives helped to deepen and clarify our analyses 
and strengthened our confidence in the findings through triangulation (Silverman, 2000). A 
further strength of the study is our use of the social marketing mix as a conceptual 
framework to guide our analyses. By critically examining recruitment from the social 
marketing perspective, we identified how issues regarding the product, price, place, 
promotion, physical environment, people, and processes all overlapped to influence 
recruitment to the trial. As far as we are aware, this is the first use of the social marketing 
mix in an empirical addiction study.  
 
Our analyses highlight how no single factor caused the recruitment difficulties experienced 
by the NEAT trial. Patients' numerous personal and practical issues competed with the trial 
and shaped their decisions about enrolment. For example, patients seeking abstinence from 
opiates were concerned that their resolve might be challenged if they met drug-using 
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associates when attending the drug treatment service for the trial (physical environment) and 
worried that employment opportunities might be compromised if newly acquired free-time 
was taken-up with trial appointments (price). Meanwhile, patients with less motivation to 
achieve abstinence tended to feel that the costs of taking part outweighed the potential 
benefits. For example, they saw reduced future contact with the drug treatment service and 
the potential loss of entitlement to health-related welfare (price) as possible negative 
consequences of relinquishing methadone or buprenorphine maintenance medications to 
join the trial.  
 
Some of our findings, such as the ‘burden’ linked to the number and frequency of trial 
appointments and perceived excessive visit schedules (price), inaccessible written materials 
(promotion), and the blind allocation to treatment or potential allocation to double placebo 
(processes) resonate with the existing literature on factors that deter people who use opiates 
from participating in pharmacological trials (Demaret et al., 2014; Melberg & Humphreys, 
2010; Thomson et al., 2008), including our own recent work (Neale et al., 2018a). Similarly, 
the prospect of an otherwise unavailable medication (product), the provision of travel passes 
and shopping vouchers (price), and hearing about the trial from a trusted service keyworker 
(people) reflect prior research on factors which encourage participation (Neale et al., 2018a; 
Oviedo-Joekes et al., 2015; Thomson et al., 2008). The influence of patient treatment 
preferences on recruitment decisions seems to reflect reports from existing naltrexone trials 
(Di Paola et al., 2014; Hulse et al., 2009; Kunøe et al., 2009; Lobmaier et al., 2010a; 
Lobmaier et al., 2010b; Tiihonen et al., 2012). 
 
Our findings also identify issues which have been less well documented in the literature. For 
example, taking part in the trial was influenced by a desire for non-pharmacological 
approaches in recovery (product). At a service level, the recommissioning of treatment 
services (place) led to the loss of a trial delivery setting and contributed to difficulties in 
securing additional recruitment centres. Such findings may reflect the increasing emphasis 
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on recovery in UK drug policy, varying ideologies about the role of medication assisted 
treatment to support recovery, and changes in the commissioning and provision of drug 
treatment services.  
 
Findings pertaining to patients’ physical and psychological concerns about naltrexone 
implants (price) suggest a suspicion of implanted medication otherwise undetected in trials 
of XR-NTX implants (Hulse et al., 2009; Krupitsky et al., 2012; Kunøe et al., 2009; Lobmaier 
et al., 2010a; Tiihonen et al., 2012; Waal et al., 2006). Notably, these concerns do not 
appear to have influenced recruitment to trials of Probuphine®, a sustained-release 
buprenorphine implant (Ling et al., 2010; Rosenthal et al., 2013). Indeed, suspicion of 
implantable formulations seems to have received little attention outside of our own empirical 
qualitative research (Neale et al., 2018b), and appears to contrast with studies on the 
acceptability of injectable XR-NTX (Ahamad et al., 2015; Haase et al., 2016; Marcus et al., 
2017; Marcus et al., 2018; Zaaijer et al., 2016). Given that the market of long-acting 
extended-release medications for OUD is expanding (Barnwal et al., 2017; Hegde, Singh & 
Sarkar, 2013; Lorman, 2018; Sigmon & Bigelow, 2016; Walsh et al., 2017), attitudes to such 
medications require further investigation, not least in light of concerns regarding the uptake 
of Probuphine® implants in the US (Titan Pharmaceuticals, 2018).  
 
To the best of our knowledge, this is the first empirical study of influences on recruitment to a 
clinical trial of an extended-release pharmacotherapy for OUD. Learning from our qualitative 
insights will therefore be most relevant to those planning and designing clinical trials of the 
effectiveness of extended-release formulations, as such trials will need to recruit large 
enough samples for meaningful analyses. For instance, the findings may help researchers to 
consider the duration of future trials given that extended-release medications are being 
developed to last up to 24 months (Reece, 2012), yet the three-month duration of the NEAT 
trial concerned patients. The findings may also help researchers consider how to balance 
the need to conduct rigorous scientific trials of extended-release medications with the need 
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for such trials to be ethical, safe, pragmatic, and attractive to the target population in real-
world settings (Nunes et al., 2016).  
 
Conducting detailed patient involvement and feasibility work is strongly advocated before 
any clinical trial commences to highlight any potential hurdles with recruitment and to identify 
the acceptability of a proposed intervention (Craig et al., 2008; O’Cathain et al., 2015). There 
is an abundance of guidance for researchers to inform the planning of clinical trials (see for 
example, Craig et al., 2008; O’Cathain et al., 2015), including our own recent checklist 
(Neale et al., 2018a). When developing interventions aimed at changing behaviours, social 
marketing prioritises the gathering of detailed knowledge of the target audience’s needs, 
wants, and preferences while allowing for the consideration of trial-specific and local 
circumstances (NSMC, 2011). Social marketing has effectively influenced health behaviour 
in a range of areas, including alcohol and illicit drugs (Stead et al., 2007). When designing 
future real-world addiction trials, there may be benefit in the prospective use of both social 
marketing theory and existing clinical trial guidance alongside one another to understand 
issues influencing recruitment in order to yield the recruitment levels required.  
 
Conclusions 
Qualitative research informed by the social marketing mix as an analytical framework yielded 
detailed insights into understanding the factors and circumstances that influenced 
recruitment to the NEAT trial. Our findings have implications for the planning and 
implementation of future addiction trials, especially trials of extended-release formulations.  
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Box 1: Key features of the Naltrexone Enhanced Addiction Treatment (NEAT) trial 
 
Clinical trial registration: ISRCTN95809946 
Design: Double-blind, double-dummy, placebo-controlled randomised clinical trial. 
Target sample: 300 patients with OUD who have completed opioid detoxification. 
Setting: Available to patients from detoxification units, primary care, community addictions 
services, residential rehabilitation services, and prison drug services in three locations in 
England. Within each location, the trial was delivered in one designated community 
addictions service.  
Inclusion criteria: 18 years or older; diagnosed with OUD as per the Diagnostic and 
Statistical Manual of Mental Disorders, Fifth Edition (DSM5); voluntarily seeking antagonist 
treatment for OUD; abstinent from opioids for at least seven days; able to provide written 
consent. 
Intervention: Random allocation to one of three groups: 1) active XR-NTX implant and 
placebo O-NTX; 2) placebo XR-NTX and active O-NTX; 3) placebo XR-NTX and placebo O-
NTX, each delivered over 12 weeks with weekly counselling. Specially produced iGen/Atral-
Cipan implants (both active and placebo naltrexone) (Castanheira do Ribatejo, Portugal), 
performed by an experienced clinician at the community addictions service. Follow-up at 16, 
24 and 36 weeks.  
Attendance: Three clinic visits each week to collect trial medication, complete safety 
assessments, complete research measures, and receive weekly relapse-prevention oriented 
counselling with a keyworker to obtain measures of drug using status.  
Reimbursement: Shopping vouchers (escalating payment schedule up to a maximum of 
£30 per week if patients attend all three trial clinic visits); provision of weekly public transport 
travel passes. 
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Table 1: Patient characteristics 
  NEAT  
patients (P)  
(n=6)  
Non-NEAT  
patients (NP) 
(n=11)  
Total 
 
(n=17)  
Gender        
Male  4  7  11  
Female  2  4  6  
Age (years)        
Mean (range)  39 (29-57)  43 (28-57)  42 (28-57)  
Ethnicity        
White British  1  5  6  
White Irish  0  1  1  
White Other  1  2  3  
Mixed White & 
Black Caribbean  
3  0  3  
Mixed White &  
Asian  
1  0  1  
Black British  0  2  2  
Arab  0  1  1  
Current treatment        
Buprenorphine  1  8  9  
Methadone  1  2  3  
Naltrexone  1  0  1  
None  3  1  4  
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Table 2: Staff characteristics  
  NEAT  
researchers  
(n=5)  
NEAT  
delivery staff  
(n=7)  
Total   
(n=12)  
Gender        
Male  5  4  9  
Female  0  3  3  
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Box 2: The Social Marketing Mix (Galli et al., 2014; NSMC, 2011) 
 
Product: the intervention which is designed to meet the needs of the target audience, and 
competition to the intervention. In this instance, the NEAT trial is the product. 
Price: the perceived financial, physical, or emotional cost/s of participating in the 
intervention. 
Place: where the product (i.e. the NEAT trial) is made available to participants. 
Promotion: the activities used to communicate information about the product (i.e. the NEAT 
trial) to the target audience. 
Physical environment: where the product (i.e. the NEAT trial) is delivered. 
People: staff who participants come into contact with about the product (i.e. the NEAT trial). 
Processes: the actions required of people to participate. 
 
 
